Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03936153 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Jul 31, 2026 Completion date: May 31, 2025 to Aug 31, 2027v12 Show 1 more changeShow less
    • Completion date: May 31, 2025 to Aug 31, 2027
  2. Primary completion date: May 31, 2024 to Dec 31, 2024 Completion date: May 31, 2024 to May 31, 2025v11 Show 1 more changeShow less
    • Completion date: May 31, 2024 to May 31, 2025
  3. Primary and study completion dates: May 31, 2023 to May 31, 2024v10
  4. Re-verified, no change to tracked fieldsv9
  5. Site details revised at 1 of 23 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 2 of 23 sitesv7
  2. Study sites revised (23)v6 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 5 of 23 sitesv5
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 22 to 23 · Start date changed from estimate of Feb 28, 2020 to Jan 20, 2020v4 Show 2 more changesShow less
    • Study sites: 22 to 23
    • Start date changed from estimate of Feb 28, 2020 to Jan 20, 2020
  5. Study sites: 0 to 22 Primary and study completion dates: Mar 30, 2023 to May 31, 2023 · Start date: Jan 31, 2020 to Feb 28, 2020v3 Show 2 more changesShow less
    • Primary and study completion dates: Mar 30, 2023 to May 31, 2023
    • Start date: Jan 31, 2020 to Feb 28, 2020
  6. Start date: Jul 30, 2019 to Jan 31, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Trial Details
NCT Number NCT03936153
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov